Article

Genetics Figure in AMD's Onset and Progression

Author(s):

Genetic factors are at work in determining who gets age-related macular degeneration, and its progression, a German team reported.

Age-related macular degeneration (AMD) is common and can cause both visual impairment and blindness.

In a German study reported in PLOS researchers looked a the genetics of the condition.

They assigned 3,444 individuals with AMD to nine categories of severity based on the characteristics of each eye.

They then genotyped 18 single nucleotide polymorphisms (SNPs) and tried to correlate them with the severity stages.

The team found there are genetic factors at play.

“The association of known genetic risk factors with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability of AMD cases and controls,” wrote Tina Schick of the Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany, and colleagues, “Genetic predisposition was also associated with the disease severity of the fellow-eye, highlighting the importance of both eyes in AMD patients”.

The team’s research builds on earlier work by others done mostly in late-stage AMD.

“Our results support these findings in more detail and suggest that there is a disease continuum from early to late AMD based on genetic factors,” the authors noted.

They found that genetic risk variants primarily established for late AMD “showed reduced effects on early stages of the disease,” and that “associations of these variants with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability”

The results also underline the importance of the second eye in AMD patients because the genetic predisposition was also associated with the disease severity of the fellow-eye.

The findings could lead to developing treatments to prevent vision loss, but first researchers need to determine the processes that lead to the onset of early AMD, as well its progression.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.